Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Corning Incorporated (GLW) vs 10X Genomics Inc (TXG) Price & Performance

Corning IncorporatedTrade
10X Genomics IncTrade

Price performance (Past 24H)

Key statistics

Corning Incorporated vs 10X Genomics Inc — how do they compare? Corning Incorporated trades at $165.53 (market cap $137.12B), while 10X Genomics Inc trades at $59.15 (market cap $7.61B). The key difference: Corning Incorporated is far larger — about 18× 10X Genomics Inc's market cap, and Corning Incorporated pays a 0.7% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.

GLWTXG
Market Cap
$137.12B$7.61B
Sector
TechnologyHealth
52-Week High
$255.79$58.57
52-Week Low
$64.52$11.34
Enterprise Value
$144.00B$7.14B
Dividend Yield
0.7%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Corning Incorporated

Corning (GLW) trades at $157.74, down 4.8% in the last session amid broader market volatility. The stock shows strong fundamental momentum with three consecutive quarterly earnings beats and projected 2026 revenue growth to $17B. Technical indicators are mixed with a neutral overall signal while valuation metrics remain elevated with a P/E of 73.36. Recent analyst upgrades highlight AI infrastructure and optical communications growth potential.

GLW presents a compelling growth story driven by AI data center demand and optical communications expansion, though premium valuation requires flawless execution. Key risks include competitive pressures in photonics and sensitivity to technology spending cycles. With 57% analyst buy ratings and a $193.33 consensus target offering 23% upside, the stock warrants consideration for growth-oriented investors despite near-term volatility.

10X Genomics Inc

TXG trades at $58.57, up 12.57% in 24 hours, reflecting strong momentum. The stock is technically bullish with moving averages supporting the uptrend, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and revenue growth, yet remains unprofitable with a negative net income margin. Recent news highlights collaborations and acquisitions expanding its genomic capabilities.

Outlook is mixed; analyst consensus is neutral with a $46 price target below current levels, indicating caution despite recent beats. Key risks include sustained losses and competitive pressures, but operational cash flow growth and strategic expansions offer potential upside for patient investors focused on long-term biotech innovation.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Corning Incorporated

Corning Inc is a leader in materials science, specializing in the production of glass, ceramics and optical fiber. The firm supplies its products for a wide range of applications, from flat-panel displays in televisions to gasoline particulate filters in automobiles to optical fiber for broadband access, with a leading share in many of its end markets.

Read more on GLW

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG